RELIGN Corporation Revenue and Competitors
Estimated Revenue & Valuation
- RELIGN Corporation's estimated annual revenue is currently $560k per year.
- RELIGN Corporation's estimated revenue per employee is $70,000
Employee Data
- RELIGN Corporation has 8 Employees.
- RELIGN Corporation grew their employee count by -11% last year.
RELIGN Corporation's People
Name | Title | Email/Phone |
---|
RELIGN Corporation Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $212.8M | 1063 | 5% | $65M | N/A |
#2 | $35.6M | 231 | 6% | N/A | N/A |
#3 | $45M | 299 | -4% | $102.6M | N/A |
#4 | $3.2M | 30 | -25% | $21.3M | N/A |
#5 | $34M | 226 | 0% | $42.9M | N/A |
#6 | $3.6M | 34 | -28% | $35M | N/A |
#7 | $0.8M | 10 | N/A | N/A | N/A |
#8 | $12.6M | 90 | -9% | N/A | N/A |
#9 | $17.4M | 124 | 0% | $96.4M | N/A |
#10 | $5.2M | 49 | -25% | $75.6M | N/A |
What Is RELIGN Corporation?
RELIGN is a startup company in the heart of Silicon Valley dedicated to innovation in arthroscopy and resection, focused on providing surgeons with best-in-class products that provide unequaled efficiency and control. We are trailblazers in the field of arthroscopy and are committed to the radical evolution of resection technology. Leveraging our years of experience, progressive research and development, and surgeon feedback, RELIGN launched the Triceraâ„¢ System. Tricera is a revolutionary, advanced system that combines ablation/coagulation, tissue resection, bone cutting, and fluid management into one unique system. The software in the Tricera System simultaneously controls these combined functions to provide surgeons with ultimate control of the arthroscopic environment. Veriflowâ„¢ inflow/outflow fluid management is incorporated directly into the Tricera Controller and automatically manages fluid pressure with unparalleled accuracy. With advanced All-in-One technology, RELIGN has created a versatile platform of surgical devices including devices that feature a smaller reciprocating electrode for aggressive tissue ablation and resection, as well as devices that offer combined aggressive bone burring, resection and ablation in a single device. These combination features provide exceptional device performance and control while allowing surgeons to switch modes without exchanging devices intraoperatively. RELIGN continues to put a strong emphasis on research and development to work towards providing quality, effective solutions for surgeons to further advance arthroscopic surgery.
keywords:N/AN/A
Total Funding
8
Number of Employees
$560k
Revenue (est)
-11%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.6M | 8 | -20% | N/A |
#2 | $0.1M | 8 | -11% | $43M |
#3 | $1.3M | 8 | -11% | N/A |
#4 | $1.2M | 8 | 0% | N/A |
#5 | $0.6M | 8 | -47% | N/A |